

**REMARKS**

Claims 1-54 were originally filed in the present application. In the Restriction Requirement mailed May 25, 2006, the Examiner restricted Claims 1-54 into the following three groups:

- I. Claims 1-16; drawn to a method of treating a skin or wound infection;
- II. Claims 17-32 and 47-54; drawn to a topical composition comprising lysostaphin and/or one more lantibiotics; and
- III. Claims 33-46, drawn to a method of decolonizing skin pathogen populations.

Applicants herein elect, without traverse, to prosecute the claims of Group III, Claims 33-46.

Applicants herein cancel claims 1-16, 17-32, and 47-54 in order to further their business interests and the prosecution of the present application, yet without acquiescing to the Examiner's arguments, and while preserving the right to prosecute the canceled (or similar) claims in the future.

Applicants also herein amend claims 33, 34, 39, 42, 43, and 45, and add new claims 55-75, each of which is drawn to the subject matter of Group III. Support for the amendments and new claims can be found throughout the application, for example on pages 26-27, lines 15-24 and 1-19, respectively, page 29, lines 9-22, page 30, lines 7-18, pages 36-37, lines 4-24 and lines 1-2, respectively, and Figure 4, among other places.

**CONCLUSION**

As such, Claims 33-46 and 55-75 are pending and under examination following entry of Applicants' response to the outstanding Restriction requirement.

Dated: June 26, 2006



David A. Casimir  
Registration No. 42,395

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
608/218-6900